Dimensional Fund Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Dimensional Fund Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.4M	Buy	651,075 +187,688	+41%	+$5.11M	﹤0.01%	2106
2026 Q2	$12.5M	Buy	463,387 +325,954	+237%	+$8.94M	﹤0.01%	2217
2026 Q1	$3.72M	Sell	137,433 -203	-0.1%	-$5.95K	﹤0.01%	2580
2025 Q4	$4.99M	Sell	137,636 -9,142	-6%	-$367K	﹤0.01%	2527
2025 Q3	$5.57M	Sell	146,778 -40,606	-22%	-$878K	﹤0.01%	2517
2025 Q2	$2.54M	Buy	187,384 +106,592	+132%	+$1.54M	﹤0.01%	2704
2025 Q1	$1.28M	Buy	80,792 +64,380	+392%	+$740K	﹤0.01%	2822
2024 Q4	$202K	Buy	+16,412	New	+$215K	﹤0.01%	3166

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Dimensional Fund Advisors's MLYS Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Mineralys Therapeutics (MLYS) stake by 41% in Q3 2026, buying an estimated $5.11M and bringing the position to 651,075 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

Dimensional Fund Advisors first reported a position in MLYS in Q4 2024 and has held it in 8 quarters since. 51 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

Dimensional Fund Advisors held 651,075 shares of Mineralys Therapeutics worth $16.4M as of Q3 2026.
Dimensional Fund Advisors bought 187,688 Mineralys Therapeutics shares in Q3 2026, an estimated $5.11M.
Mineralys Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2106 holding.
Dimensional Fund Advisors first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 8 quarters since.
51 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.